Summary
Pyrazolam is notable for producing proportionally greater anxiety suppression than sedation compared to other benzodiazepines, making it more functional but also increasing delusions of sobriety. Originally developed at Hoffman-La Roche in the 1970s and rediscovered on the research chemical market in 2012. Unlike most benzodiazepines, pyrazolam does not undergo metabolism and is excreted unchanged in urine. Illegal in the UK (Class C), Germany, Sweden, Switzerland, Turkey, and other jurisdictions.
Dose Information
| ROA | Light | Common | Strong | Heavy |
|---|---|---|---|---|
| Oral | 0.5-0.75mg | 0.75-1.5mg | 1.5-3mg | 3mg+ |
Light
Common
Strong
Heavy
Onset, Duration & After-effects
| ROA | Onset | Peak | Offset | After Effects | Total |
|---|---|---|---|---|---|
| Oral | 10-15 min | 1-3 hrs | 4-6 hrs | 60-0 min | 300-0 min |
Tolerance
Build-up
develops over 1–4 weeks of daily use; hypnotic tolerance faster than anxiolytic tolerance
Reset
weeks to months depending on half-life and duration of use; taper recommended
Effects
Positive
- Muscle relaxation
- Anxiolytic
- Muscle Relaxant
- Physical euphoria
Negative
- Respiratory depression
- Motor impairment
- Sedation
- Sedative
- Dystaxia
- Hypnotic
Positive
- Anxiety suppression
- Dream potentiation
Negative
- Delusions of sobriety
- Amnesia
- Thought deceleration
- Analysis suppression
- Compulsive redosing
- Motor control loss
- Dizziness
- Information processing suppression
Positive
- Increased libido
- Appetite enhancement
Negative
- Disinhibition
- Acuity suppression
- Visual acuity suppression
- Acuity Suppression
- Decreased Libido
- Double vision
- Dulled perception
- Perception of bodily heaviness